Algorithms give computers step-by-step instructions to complete tasks accurately.Good algorithms improve software speed, ...

Netflix's hidden genre codes bypass the algorithm entirely and drop you straight into whatever category you're actually in ...

Building a model capable of RSI would require automating a range of specialist tasks currently carried out by humans. At ...

Anthropic reveals that Claude now writes over 80% of its production code, with engineers shipping 8x more code per quarter than in 2024. The company’s new Anthropic Institute paper maps the path to ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

The artificial intelligence giant said a “brake pedal” was needed to protect humanity from self-improving models. The proposal could have big consequences. By Andrew Ross Sorkin Bernhard Warner Sarah ...

Anthropic said its powerful new AI model, Mythos, could be dangerous in the wrong hands. WSJ’s Nicole Nguyen explains why and shares some cybersecurity tips for the average tech user. Photo: Sean ...

Anthropic says AI could soon improve without human intervention Development pause will allow society to deal with AI's implications, startup says Previous attempts to halt AI progress have not been ...

Claude now authors over 80% of the code Anthropic merges into production. Engineers shipped 8 times as much code per day in 2026 as in 2024. On a code-speedup test Claude hit 52x, versus 4x for ...

Companies have been developing AI very quickly to stay ahead of the market, but Favaro and Clark argue that a slowdown would allow more time to deal with the technology’s implications. US-based AI ...

A coding mistake in several Microsoft 365 Android applications resulted in the exposure of user accounts to compromise at massive scale, demonstrating once again how dropping the ball on securing ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...